BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 21509038)

  • 21. Comparison of the antitumor effects of an MDM2 inhibitor, nutlin-3, in feline lymphoma cell lines with or without p53 mutation.
    Mochizuki H; Goto-Koshino Y; Sato M; Fujino Y; Ohno K; Tsujimoto H
    Vet Immunol Immunopathol; 2012 Jun; 147(3-4):187-94. PubMed ID: 22578852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
    Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
    Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.
    Michaelis M; Rothweiler F; Barth S; Cinatl J; van Rikxoort M; Löschmann N; Voges Y; Breitling R; von Deimling A; Rödel F; Weber K; Fehse B; Mack E; Stiewe T; Doerr HW; Speidel D; Cinatl J
    Cell Death Dis; 2011 Dec; 2(12):e243. PubMed ID: 22170099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
    Zanjirband M; Edmondson RJ; Lunec J
    Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity.
    Voon YL; Ahmad M; Wong PF; Husaini R; Ng WT; Leong CO; Lane DP; Khoo AS
    Oncol Rep; 2015 Oct; 34(4):1692-700. PubMed ID: 26252575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.
    Henze J; Mühlenberg T; Simon S; Grabellus F; Rubin B; Taeger G; Schuler M; Treckmann J; Debiec-Rychter M; Taguchi T; Fletcher JA; Bauer S
    PLoS One; 2012; 7(5):e37776. PubMed ID: 22662219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
    Canner JA; Sobo M; Ball S; Hutzen B; DeAngelis S; Willis W; Studebaker AW; Ding K; Wang S; Yang D; Lin J
    Br J Cancer; 2009 Sep; 101(5):774-81. PubMed ID: 19707204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
    Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
    Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.
    Michaelis M; Rothweiler F; Agha B; Barth S; Voges Y; Löschmann N; von Deimling A; Breitling R; Doerr HW; Rödel F; Speidel D; Cinatl J
    Cell Death Dis; 2012 Apr; 3(4):e294. PubMed ID: 22476102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
    Zheng T; Wang J; Chen X; Meng X; Song X; Lu Z; Jiang H; Liu L
    Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis.
    Davaadelger B; Perez RE; Zhou Y; Duan L; Gitelis S; Maki CG
    Cancer Biol Ther; 2017 Nov; 18(11):895-903. PubMed ID: 28696156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
    Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
    Hasegawa H; Yamada Y; Iha H; Tsukasaki K; Nagai K; Atogami S; Sugahara K; Tsuruda K; Ishizaki A; Kamihira S
    Leukemia; 2009 Nov; 23(11):2090-101. PubMed ID: 19710698
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.
    Jones RJ; Bjorklund CC; Baladandayuthapani V; Kuhn DJ; Orlowski RZ
    Mol Cancer Ther; 2012 Oct; 11(10):2243-53. PubMed ID: 22933706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia.
    Kojima K; Konopleva M; Tsao T; Nakakuma H; Andreeff M
    Blood; 2008 Oct; 112(7):2886-95. PubMed ID: 18633130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
    Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
    J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3.
    Du W; Wu J; Walsh EM; Zhang Y; Chen CY; Xiao ZX
    J Biol Chem; 2009 Sep; 284(39):26315-21. PubMed ID: 19648117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
    Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells.
    Vaseva AV; Marchenko ND; Moll UM
    Cell Cycle; 2009 Jun; 8(11):1711-9. PubMed ID: 19411846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.